TG-101348 (Fedratinib, SAR302503)
Catalog No. A11082
TG-101348 (Fedratinib,SAR302503)是Janus相关激酶2的口服生物利用型,ATP竞争性和选择性抑制剂,在无细胞试验中IC50为3 nM,作用于JAK2比作用于JAK1和JAK3选择性高35和334倍,具有潜在的抗肿瘤活性。
Catalog Num | A11082 |
---|---|
M. Wt | 524.7 |
Formula | C27H36N6O3S |
Purity | >98% |
Storage | at -20°C 3 years Powder |
CAS No. | 936091-26-8 |
Synonyms | SAR302503,TG101348,TG101348 |
SMILES | CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4 |
TG-101348 (Fedratinib,SAR302503)是Janus相关激酶2的口服生物利用型,ATP竞争性和选择性抑制剂,在无细胞试验中IC50为3 nM,作用于JAK2比作用于JAK1和JAK3选择性高35和334倍,具有潜在的抗肿瘤活性。
Targets
JAK2 (Cell-free assay) | JAK2 (V617F) (Cell-free assay) | FLT3 (Cell-free assay) | RET (Cell-free assay) | |
3 nM | 3 nM | 15 nM | 48 nM |
In vitro | DMSO | 90 mg/mL (171.53 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 19.06 mL | 95.29 mL | 190.59 mL |
0.5 mM | 3.81 mL | 19.06 mL | 38.12 mL |
1 mM | 1.91 mL | 9.53 mL | 19.06 mL |
5 mM | 0.38 mL | 1.91 mL | 3.81 mL |
*The above data is based on the productmolecular weight 524.7. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.